Vito Lorusso

Summary

Country: Italy

Publications

  1. pmc Bevacizumab in the treatment of HER2-negative breast cancer
    Vito Lorusso
    Oncologic Institute, Vito Fazzi Hospital, Lecce, Italy
    Biologics 2:813-21. 2008
  2. doi request reprint Novel plant-derived target drugs: a step forward from licorice?
    Vito Lorusso
    National Cancer Research Centre, Istituto Oncologico Giovanni Paolo II, viale Orazio Flacco 65, 70124, Bari, Italy
    Expert Opin Ther Targets 17:333-5. 2013
  3. ncbi request reprint Which role for EGFR therapy in breast cancer?
    Vito Lorusso
    Medical Oncology Unit, Hospital Vito Fazzi, Lecce, Italy
    Front Biosci (Schol Ed) 4:31-42. 2012
  4. pmc Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy
    Vito Lorusso
    Oncology Unit, Vito Fazzi Hospital, Lecce, Italy
    Support Care Cancer 20:3241-6. 2012
  5. ncbi request reprint A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer
    Vito Lorusso
    Medical Oncology Department, Oncology Institute of Bari, Italy
    Clin Breast Cancer 4:138-41. 2003
  6. ncbi request reprint Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer
    V Lorusso
    Operative Unit of Medical Oncology, Oncology Institute of Bari, Italy
    Ann Oncol 13:1862-7. 2002
  7. ncbi request reprint Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies
    Vito Lorusso
    Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy
    Breast 19:214-8. 2010
  8. doi request reprint Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results
    V Lorusso
    Oncology Unit, Vito Fazzi Hospital, Lecce, Italy
    Support Care Cancer 17:1469-73. 2009
  9. ncbi request reprint Role of liposomal anthracyclines in breast cancer
    V Lorusso
    Medical Oncology Unit, Vito Fazzi Hospital, Lecce
    Ann Oncol 18:vi70-3. 2007
  10. ncbi request reprint Topotecan in the treatment of brain metastases. A phase II study of GOIM (Gruppo Oncologico dell'Italia Meridionale)
    Vito Lorusso
    Medical Oncology Department, Oncology Institute, Via Amendola 209, 70123 Bari, Italy
    Anticancer Res 26:2259-63. 2006

Detail Information

Publications75

  1. pmc Bevacizumab in the treatment of HER2-negative breast cancer
    Vito Lorusso
    Oncologic Institute, Vito Fazzi Hospital, Lecce, Italy
    Biologics 2:813-21. 2008
    ..Future research will investigate bevacizumab in the neoadjuvant or adjuvant setting, where even more potential may exist for these patients...
  2. doi request reprint Novel plant-derived target drugs: a step forward from licorice?
    Vito Lorusso
    National Cancer Research Centre, Istituto Oncologico Giovanni Paolo II, viale Orazio Flacco 65, 70124, Bari, Italy
    Expert Opin Ther Targets 17:333-5. 2013
    ..These effects may be mediated through inhibition of p38, PI3K/Akt and NF-κB signaling pathways. Thus, low concentration of ISL may have therapeutic potential in the treatment of aggressive breast carcinoma and other neoplasms...
  3. ncbi request reprint Which role for EGFR therapy in breast cancer?
    Vito Lorusso
    Medical Oncology Unit, Hospital Vito Fazzi, Lecce, Italy
    Front Biosci (Schol Ed) 4:31-42. 2012
    ..This paper focuses on the therapeutic strategy for treatment of HER2 overexpressing breast cancer in advanced stages of disease, as well as in the adjuvant and neo-adjuvant settings...
  4. pmc Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy
    Vito Lorusso
    Oncology Unit, Vito Fazzi Hospital, Lecce, Italy
    Support Care Cancer 20:3241-6. 2012
    ....
  5. ncbi request reprint A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer
    Vito Lorusso
    Medical Oncology Department, Oncology Institute of Bari, Italy
    Clin Breast Cancer 4:138-41. 2003
    ....
  6. ncbi request reprint Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer
    V Lorusso
    Operative Unit of Medical Oncology, Oncology Institute of Bari, Italy
    Ann Oncol 13:1862-7. 2002
    ....
  7. ncbi request reprint Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies
    Vito Lorusso
    Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy
    Breast 19:214-8. 2010
    ....
  8. doi request reprint Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results
    V Lorusso
    Oncology Unit, Vito Fazzi Hospital, Lecce, Italy
    Support Care Cancer 17:1469-73. 2009
    ..Moreover, we evaluated the amount of their food intake (FI) in the week following therapy, in order to measure any reduction of calories consumption related to Chemotherapy-induced nausea and vomiting (CINV)...
  9. ncbi request reprint Role of liposomal anthracyclines in breast cancer
    V Lorusso
    Medical Oncology Unit, Vito Fazzi Hospital, Lecce
    Ann Oncol 18:vi70-3. 2007
    ..This review will focus on both liposomal formulations of doxorubicin which are approved in Europe and Canada for use in patients with metastatic breast cancer...
  10. ncbi request reprint Topotecan in the treatment of brain metastases. A phase II study of GOIM (Gruppo Oncologico dell'Italia Meridionale)
    Vito Lorusso
    Medical Oncology Department, Oncology Institute, Via Amendola 209, 70123 Bari, Italy
    Anticancer Res 26:2259-63. 2006
    ..Topotecan is able to cross the blood-brain barrier (BBB) and has been demonstrated to be active in brain metastases from small cell lung cancer (SCLC)...
  11. ncbi request reprint Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale)
    V Lorusso
    Medical Oncology Unit, Vito Fazzi Hospital, Lecce
    Ann Oncol 17:vii15-7. 2006
    ..Actually, the availability of oral formulation for vinorelbine allows a full oral combination of the two agents. The aim of this study was to evaluate the activity and toxicity of this novel combination...
  12. pmc Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer
    V Lorusso
    Operative Unit of Medical Oncology, Oncology Institute, Bari, Italy
    Br J Cancer 88:491-5. 2003
    ..In conclusion, the doses of 10 mg m(-2) (day 1) for mitoxantrone and 1000 mg m(-2) for gemcitabine (days 1-8) every 3 weeks resulted active and safe in MBC. Further investigations in less heavily pretreated patients are warranted...
  13. ncbi request reprint Role of gemcitabine in metastatic breast cancer patients: a short review
    Nicola Silvestris
    Operative Unit of Medical Oncology, Moscati General Hospital, Via per Martina Franca, 74100 Taranto, Italy
    Breast 17:220-6. 2008
    ..4 months), but without a significant difference in overall survival; the incidence of haematologic toxicity was higher in the group treated with combined therapy. Novel gemcitabine combinations are being investigated in phase II studies...
  14. doi request reprint First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale
    Vittorio Gebbia
    Medical Oncology Unit, University of Palermo, La Maddalena Clinic for Cancer, Palermo, Italy
    Lung Cancer 69:218-24. 2010
    ..The impact of these regimens on patients' QoL as well as symptoms control and type and grading chemo-related side-effects has been compared prospectically...
  15. ncbi request reprint Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium
    Vito Lorusso
    Operative Unit of Medical Oncology, Oncology Institute of Bari, Via Amendola 209, Bari 70126, Italy
    Oncol Rep 13:283-7. 2005
    ..Larger and more powered studies are needed to exactly define the role of paclitaxel in this combination...
  16. ncbi request reprint What news in urological cancer
    Vito Lorusso
    Medical Oncology Dept, Oncology Institute, Bari
    Tunis Med 83:75-6. 2005
  17. ncbi request reprint Present status and perspectives in the treatment of hormone-refractory prostate cancer
    Nicola Silvestris
    Operative Unit of Medical Oncology, Oncology Center Giorgio Porfiri, Latina, Italy
    Oncology 69:273-82. 2005
    ..Indeed, investigations into the pathophysiology of this malignancy, novel biological agents, skeletal protectants and radiopharmaceuticals are expanding the clinician's armamentarium and improving the patient's outcome...
  18. ncbi request reprint Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial
    Vito Lorusso
    Department of Medical Oncology, Oncology Institute, Via Amendola 209, 70126 Bari, Italy
    Oncol Rep 14:1547-51. 2005
    ..7%. Nevertheless, the still low response rate and the shortness of median survival indicates the need for more effective second line treatments in this disease...
  19. doi request reprint Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer
    Daniele Vergara
    Laboratory of General Physiology, Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy
    Nanomedicine 8:891-9. 2012
    ..The small size and functional versatility of these nanoparticles, combined with their ability to incorporate various drugs, indicates that lapatinib/PTX nanocolloids may have in vivo therapeutic applications...
  20. ncbi request reprint Amifostine as chemoprotectant in metastatic breast cancer patients treated with doxorubicin
    Annamaria Catino
    Operative Unit of Medical Oncology, Oncology Institute of Bari, Italy
    Oncol Rep 10:163-7. 2003
    ..In conclusion, this study suggests that amifostine can reduce doxorubicin related toxicity, thus improving the patients' quality of life and the efficacy/toxicity ratio of this drug...
  21. doi request reprint A new mutation of BRCA2 gene in an Italian healthy woman with familial breast cancer history
    Maurizio Pisanò
    Molecular Biology and Experimental Oncology Lab, Oncological Hospital, Lecce, Italy
    Fam Cancer 10:65-71. 2011
    ..Since this mutant protein not performs a translocation into the nucleus, it is fully non-functional...
  22. doi request reprint Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal
    Andrea Tinelli
    Department of Gynaecology and Obstetrics, Vito Fazzi Hospital, Lecce, Italy
    Cancer Metastasis Rev 29:339-50. 2010
    ..Prophylactic surgery has been shown to effectively decrease cancer risk, and it has the possibility to substantially reduce ovarian cancer mortality...
  23. ncbi request reprint Dasatinib: an anti-tumour agent via Src inhibition
    Antonio Gnoni
    Medical Oncology Unit, Hospital Vito Fazzi, Lecce, Italy
    Curr Drug Targets 12:563-78. 2011
    ....
  24. ncbi request reprint Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (Review)
    Enrico Crucitta
    Operative Unit of Medical Oncology, Oncology Institute of Bari, Italy
    Int J Oncol 20:1283-8. 2002
    ..New data on exemestane are forthcoming both in the adjuvant and neoadjuvant setting, which could improve the management of early breast cancer in the future...
  25. ncbi request reprint Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC
    M De Lena
    Ospedale Oncologico di Bari, Bari, Italy
    Lung Cancer 48:129-35. 2005
    ..The availability of an oral form of vinorelbine appeared as a particularly convenient way to provide a consolidation treatment to patients who have achieved an objective response or stable disease...
  26. ncbi request reprint Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer
    V Lorusso
    Operative Unit of Medical Oncology, Oncology Hospital, Bari, Italy
    J Clin Oncol 18:405-11. 2000
    ..To determine the maximum-tolerated dose of gemcitabine when combined with a fixed dose of vinorelbine in the treatment of non-small-cell lung cancer (NSCLC) and to evaluate in a phase II trial the activity of this combination...
  27. ncbi request reprint Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells
    Daniele Vergara
    Laboratory of General Physiology, Department of Biological and Environmental Sciences and Technologies, University of Salento, via Monteroni 73100, Lecce, Italy
    Cancer Lett 310:1-8. 2011
    ..In summary, these data provide new evidence of the inhibitory effect of resveratrol on EGF-induced EMT cell transformation...
  28. ncbi request reprint Mitoxantrone, L-leucovorin and 5-fluorouracil: an effective and well tolerated first-line treatment for advanced breast cancer
    V Lorusso
    Medical Oncology Operative Unit, Oncology Institute of Bari, Italy
    Tumori 85:60-4. 1999
    ..The aim of this study was to evaluate the activity of this combination in patients not previously submitted to chemotherapy...
  29. ncbi request reprint Predictive factors to targeted treatment in gastrointestinal carcinomas
    Nicola Silvestris
    Medical Oncology Unit, National Cancer Research Centre Giovanni Paolo II, Bari, Italy
    Cancer Biomark 14:151-62. 2014
    ....
  30. doi request reprint Which patients with estrogen receptor-positive early breast cancer should be treated with adjuvant chemotherapy?
    Vincenzo Emanuele Chiuri
    Oncologia Medica, Ospedale V Fazzi, Lecce, Italy
    Oncology 77:18-22. 2009
    ....
  31. ncbi request reprint Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale
    Giuseppe Colucci
    Medical and Experimental Oncology Unit, Oncology Institute, Via Amendola 209, 70126 Bari, Italy
    J Clin Oncol 23:4866-75. 2005
    ..We performed this phase III study to compare the irinotecan, leucovorin (LV), and fluorouracil (FU) regimen (FOLFIRI) versus the oxaliplatin, LV, and FU regimen (FOLFOX4) in previously untreated patients with advanced colorectal cancer...
  32. ncbi request reprint Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study
    F Giotta
    Oncology Institute, Bari, Italy
    Ann Oncol 18:vi66-9. 2007
    ....
  33. ncbi request reprint High efficacy of paclitaxel and doxorubicin as first-line therapy in advanced breast cancer: a phase I-II study
    M De Lena
    Medical Oncology Division of the Oncology Institute, Bari, Italy
    J Chemother 12:367-73. 2000
    ..8 months and overall survival 27.8 months. The main clinical toxicity was neutropenia (grade III-IV) of short duration (94%). Two patients developed cardiac toxicity. The combination TAX+ADM is very effective in advanced breast cancer...
  34. ncbi request reprint Rationale for the use of gemcitabine in breast cancer (Review)
    N Silvestris
    Operative Unit of Medical Oncology, Oncology Center Giorgio Porfiri, Latina, Italy
    Int J Oncol 24:389-98. 2004
    ..Phase III trials of gemcitabine combinations compared to standard regimens are ongoing with the aim to assess the independent contribution of gemcitabine...
  35. ncbi request reprint Third-line trabectedin for a metastatic desmoplastic small round cell tumour treated with multimodal therapy
    Anna Elisabetta Brunetti
    Medical Oncology Unit, National Cancer Institute Giovanni Paolo II, Bari, Italy
    Anticancer Res 34:3683-8. 2014
    ..Conclusion: Trabectedin may be a treatment option in multimodal therapy for the management of DSRCT and warrants further research to explore the impact of trabectedin in the treatment of this disease. ..
  36. doi request reprint Complete response to second line Paclitaxel every 2 weeks of eyelid kaposi sarcoma: a case report
    Anna Elisabetta Brunetti
    Scientific Direction, Hematology Unit, Medical and Experimental Oncology Unit, Cancer Institute Giovanni Paolo II, Bari, Italy
    Ophthal Plast Reconstr Surg 29:e114-5. 2013
    ..In conclusion, eyelid Kaposi sarcoma was successfully treated with paclitaxel every 2 weeks, obtaining a complete response...
  37. ncbi request reprint Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment
    Girolamo Ranieri
    Girolamo Ranieri, Ilaria Marech, Veronica Goffredo, Cosmo Damiano Gadaleta, Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre, Cancer Institute Giovanni Paolo II, 70124 Bari, Italy
    World J Gastroenterol 20:486-97. 2014
    ..Actually, a number of clinical studies are ongoing testing these agents in combination with TACE or RFA. In this paper, we have reviewed the most recent preclinical and clinical results of such trials...
  38. ncbi request reprint Target therapies in pancreatic carcinoma
    Nicola Silvestris
    Medical Oncology Unit, National Cancer Research Centre Istituto Tumori Giovanni Paolo II, Viale Orazio Flacco, 65, 70124 Bari, Italy
    Curr Med Chem 21:948-65. 2014
    ..The knowledge of biologic and molecular aspects of pancreatic cancer can be the basis for future therapeutic developments. ..
  39. ncbi request reprint Radiofrequency ablation of 40 lung neoplasms: preliminary results
    Cosmo Gadaleta
    Unità Operativa di Radiologia Interventistica, Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Oncologico, Via Amendola 209, Bari 70126, Italy
    AJR Am J Roentgenol 183:361-8. 2004
    ..This study was performed to evaluate the technical feasibility, the safety, and the efficacy of lung radiofrequency thermal ablation...
  40. ncbi request reprint Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins
    Stefania Tommasi
    Clinical Experimental Oncology Laboratory, National Cancer Institute, Via Amendola 209, 70126 Bari, Italy
    Int J Cancer 120:2078-85. 2007
    ..only 7% of patients with low expression (35% vs. 7%, p < 0.002). Our study suggests that Class III beta-tubulin tumor expression could be considered a predictive biomarker of paclitaxel-clinical resistance for breast cancer patients...
  41. ncbi request reprint C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy
    Addolorata Casamassima
    Department of Experimental Oncology, Laboratory of Immunology, Oncology Institute, Via Amendola 209, 70126 Bari, Italy
    J Urol 173:52-5. 2005
    ....
  42. doi request reprint Laparoscopical management ovarian early sex cord-stromal tumors in postmenopausal women: a proposal method
    Andrea Tinelli
    Division of Experimental Endoscopic Surgery, Imaging, Minimally Invasive Therapy and Technology, Department of Obstetrics and Gynaecology, Vito Fazzi Hospital, P zza Muratore, 73100, Lecce, Italy
    Arch Gynecol Obstet 283:87-91. 2011
    ..Ovarian sex-cord stromal tumor (SCST) comprises 5% of the ovarian neoplasm; it occurs as an ovarian mass or hemoperitoneum, and the surgical management of SCST is not well defined at early stage and in adult patients...
  43. doi request reprint Emergency endovascular nanopharmacologic treatment in advanced gynecological cancers
    Andrea Tinelli
    Department of Gynecology and Obstetrics, Division of Experimental Endoscopic Surgery, Imaging, Minimally Invasive Therapy, and Technology, Vito Fazzi Hospital, Lecce, Italy
    Int J Gynecol Cancer 20:1250-5. 2010
    ....
  44. ncbi request reprint Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy)
    M De Lena
    Division of Medical Oncology, Oncology Institute, Bari, Italy
    Haematologica 78:230-5. 1993
    ..Radiotherapy alone has provided a good response rate but also a high percentage of recurrences, and therefore many studies have been initiated to evaluate combined modality treatment...
  45. ncbi request reprint AIDS-related non-Hodgkin's lymphoma: clinico-pathological characteristics and therapeutic strategies (review)
    Nicola Silvestris
    Operative Unit of Medical Oncology, ASL of Frosinone, Bari, Italy
    Int J Oncol 20:611-5. 2002
    ..We reviewed the main clinico-pathological features of this disease and analysed its pathogenetic mechanisms with potential therapeutic implications...
  46. ncbi request reprint Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer
    A Paradiso
    Clinical Experimental Oncology Laboratory, Senology Unit, Histopathology Service, and Medical Oncology Unit, National Oncology Institute, Bari, Italy
    J Clin Oncol 19:3929-37. 2001
    ..The aim of the present study was to investigate whether patients with fast-proliferating, node-negative breast cancer could benefit from adjuvant chemotherapy with fluorouracil, epirubicin, and cyclophosphamide (FEC)...
  47. ncbi request reprint M-VECA (methotrexate, vinblastine, epidoxorubicin and carboplatin) in the treatment of advanced urothelial carcinoma
    V Lorusso
    Medical Oncology Division, Oncology Institute, Bari, Italy
    Tumori 79:191-4. 1993
    ..However, the possibility of substituting carboplatin for cisplatin as neoadjuvant therapy for less advanced stages needs further investigation in randomized studies...
  48. ncbi request reprint Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer
    A Paradiso
    Clinical Experimental Oncology Laboratory, National Cancer Institute, Via Amendola 209, 70125 Bari, Italy
    Ann Oncol 16:iv14-19. 2005
    ....
  49. ncbi request reprint [New therapeutic prospects in microcytoma]
    V Lorusso
    Oncologia Medica, Istituto Oncologico, Bari, Italy
    Minerva Endocrinol 26:239-41. 2001
    ....
  50. ncbi request reprint Extensive small cell lung cancer: standard and experimental treatment approaches in elderly patients
    N Silvestris
    Operative Unit of Medical Oncology, Hospital Santa Maria Goretti, Latina, Italy
    Ann Oncol 17:ii64-66. 2006
  51. ncbi request reprint Unusual response to second-line single-agent gemcitabine in locally advanced primary leiomyosarcoma of the lung: a case report
    N Silvestris
    Operative Unit of Medical Oncology, Oncology Institute of Bari, Italy
    J Chemother 15:507-9. 2003
    ..Gemcitabine may represent an alternative to the best supportive care in patients affected with soft tissue sarcoma who fail first-line chemotherapy...
  52. ncbi request reprint Sequential alternate administration of tamoxifen and medroxyprogesterone acetate in advanced breast cancer: clinical-biological randomized study
    M De Lena
    Oncology Division, Oncology Institute, Bari, Italy
    Tumori 76:190-5. 1990
    ..In conclusion, our study demonstrated that while the manipulation of hormone receptors seems possible, results indicating better overall survival and time to progression were not obtained with alternate sequential TAM-MPA therapy...
  53. pmc Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin
    Sabino Strippoli
    Medical Oncology Department, National Cancer Research Centre Giovanni Paolo II, Bari, Italy
    BMC Complement Altern Med 13:199. 2013
    ....
  54. pmc Ovarian cancer biomarkers: a focus on genomic and proteomic findings
    Andrea Tinelli
    Department of Obstetrics and Gynecology, Vito Fazzi Hospital, Lecce, Italy
    Curr Genomics 8:335-42. 2007
    ....
  55. ncbi request reprint Prostate carcinoma
    Vito Lorusso
    Medical Oncology Department, Oncology Institute, Bari
    Tumori 88:S125-7. 2002
  56. ncbi request reprint Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study
    M De Lena
    Medical Oncology Department, Oncology Institute of Bari, Via Amendola 209, 70126 Bari, Italy
    Eur J Cancer 37:364-8. 2001
    ..Alopecia, nausea and vomiting (Grade 3) were observed in 33 (94%) and 5 (14%) patients, respectively. In conclusion, the combination of CDDP/paclitaxel plus LND is active and tolerable in the treatment of advanced ovarian cancer...
  57. ncbi request reprint Systemic chemotherapy for patients with advanced and metastatic bladder cancer: current status and future directions
    V Lorusso
    Operative Unit of Medical Oncology, Oncology Institute of Bari, Bari, Italy
    Ann Oncol 16:iv85-89. 2005
  58. ncbi request reprint Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum
    M De Lena
    Medical Oncology Division, Oncology Institute, Bari, Italy
    J Clin Oncol 15:3208-13. 1997
    ..The aim of this study was to confirm the potentiating or reverting activity of LND on CDDP activity obtained in experimental models in a phase II study of advanced ovarian cancer patients previously treated with platinum-based regimens...
  59. ncbi request reprint Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different nosological entities?
    M Guida
    Medical Oncology Division, Oncology Institute, Bari, Italy
    Tumori 80:370-7. 1994
    ..Indicators of disease activity and extension, and of a possible evolution to multiple myeloma, have not been identified as yet...
  60. ncbi request reprint A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108
    Pasquale Comella
    Division of Medical Oncology A, Department of Medical Oncology, National Tumour Institute, Via M Semmola, 80131 Naples, Italy
    Crit Rev Oncol Hematol 53:133-9. 2005
    ..Progression of disease occurred in 23 (66%) patients, and 18 (51%) died. The actuarial median progression-free and survival time were 6.9 and 14.1 months, respectively...
  61. ncbi request reprint Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108
    Pasquale Comella
    Department of Medical Oncology, National Tumor Institute, Naples, Italy
    Cancer 104:282-9. 2005
    ..Capecitabine (an oral fluoropyrimidine) may be an effective, well tolerated, and more convenient alternative to 5-FU/LV in combination with oxaliplatin, especially in older patients...
  62. ncbi request reprint Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma
    Luigi Portalone
    16th Pneumo Oncology Unit, C Forlanini Hospital, Rome, Italy
    Tumori 91:15-8. 2005
    ..The role of interleukin-2 in maintenance therapy for malignant pleural mesothelioma is encouraging and requires further study...
  63. ncbi request reprint Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients
    Alessandra Fabi
    Division of Medical Oncology A, Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
    Cancer Chemother Pharmacol 57:615-23. 2006
    ....
  64. ncbi request reprint Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer
    Alessandra Gennari
    National Cancer Research Institute, Largo Rosanna Benzi, Genoa, Italy
    J Clin Oncol 24:3912-8. 2006
    ..This randomized study compared maintenance paclitaxel with control in metastatic breast cancer patients not experiencing progression after first-line anthracycline/paclitaxel combination chemotherapy...
  65. doi request reprint Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?
    Diego Cortinovis
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    J Thorac Oncol 3:405-11. 2008
    ..In this setting, docetaxel (D) has shown efficacy and irinotecan (I) has only recently been introduced. This study was initiated to explore the activity and tolerability of three D + I regimens in platinum pretreated NSCLC patients...
  66. ncbi request reprint Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial
    Giacomo Carteni
    AORNA Cardarelli, Napoli, Italy
    Oncologist 11:841-8. 2006
    ..This study evaluated the efficacy and safety of zoledronic acid in breast cancer patients with newly diagnosed bone metastases...
  67. ncbi request reprint Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design
    Alfredo Berruti
    Oncologia Medica, Azienda Ospedaliera San Luigi, Orbassano, Italy
    J Clin Oncol 20:4150-9. 2002
    ..To investigate the value of the addition of either cisplatin (CDDP) or lonidamine (LND) to epirubicin (EPI) in the first-line treatment of advanced breast cancer...
  68. ncbi request reprint Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Clin Oncol 25:4663-9. 2007
    ..Two phase I/II trials were done to evaluate the feasibility of cisplatin combined with gemcitabine or vinorelbine in elderly patients with advanced non-small-cell lung cancer (NSCLC)...
  69. ncbi request reprint Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial
    Jean Yves Douillard
    Centre Rene Gauducheau, Nantes, France
    Lancet Oncol 7:719-27. 2006
    ..We aimed to compare the effect of adjuvant vinorelbine plus cisplatin versus observation on survival in patients with completely resected NSCLC...
  70. ncbi request reprint Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II study
    Sergio Palmeri
    Department of Oncology, Division of Medical Oncology, University of Palermo, Palermo, Italy
    Cancer 107:2898-905. 2006
    ..To date, the standard treatment for patients who have carcinoma of unknown primary site has not been established...
  71. ncbi request reprint Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer
    Alessandro Morabito
    Division of Medical Oncology, San Filippo Neri Hospital, Rome, Italy
    Breast Cancer Res Treat 86:249-57. 2004
    ..The present study was designed with the aim of evaluating the tolerability and activity of pegylated liposomial doxorubicin (PLD) in combination with weekly docetaxel as first line treatment of advanced breast cancer...
  72. ncbi request reprint Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials
    Pasquale Comella
    Division of Medical Oncology A, National Tumor Institute, Naples, and Division of Medical Oncology, University Medical School, Cagliari, Italy
    Clin Colorectal Cancer 5:203-10. 2005
    ....
  73. ncbi request reprint Communication near the end of life
    Silvia De Padova
    Tumori 94:621; author reply 621-2. 2008
  74. ncbi request reprint Darbepoetin alpha coming of age
    Paolo Pedrazzoli
    Falck Medical Oncology Unit, Niguarda Ca Granda Hospital, Milano, Italy
    Anticancer Res 27:4419-24. 2007
    ..However, it is also clear from recent reports that scrutiny on the safe use of these drugs is still required...
  75. ncbi request reprint Effect of tamoxifen in an experimental model of breast tumor studied by dynamic contrast-enhanced magnetic resonance imaging and different contrast agents
    Pasquina Marzola
    Dipartimento di Scienze Morfologico Biomediche, Sezione di Anatomia ed Istologia, Universita di Verona, Verona
    Invest Radiol 40:421-9. 2005
    ....